Daxas Approved In EU With Narrow Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Nycomed's drug gets the green light to treat severe COPD with chronic bronchitis in adult patients with a history of frequent exacerbations, as an add-on to bronchodilator treatment.
You may also be interested in...
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.
Nycomed To Beef Up Sales In China Through Buyout; Bets On India For Global API Supplies
MUMBAI - Having established itself firmly among the top 10 pharma companies in Russia, Zurich-headquartered Nycomed now plans to dig deeper into the fast-growing Chinese market through the acquisition of a sales and distribution team